How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

57,022 results for

Alcoholism Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Managed Alcohol Programs for Patients with Alcohol Addiction: Clinical Effectiveness

Managed Alcohol Programs for Patients with Alcohol Addiction: Clinical Effectiveness Managed Alcohol Programs for Patients with Alcohol Addiction: Clinical Effectiveness | CADTH.ca Find the information you need Managed Alcohol Programs for Patients with Alcohol Addiction: Clinical Effectiveness Managed Alcohol Programs for Patients with Alcohol Addiction: Clinical Effectiveness Published on: January 27, 2017 Project Number: RB1053-000 Product Line: Research Type: Devices and Systems Report Type (...) : Summary of Abstracts Result type: Report Question What is the clinical effectiveness of managed alcohol programs for patients with alcohol addiction? Key Message Two systematic reviews and one non-randomized study were identified regarding the clinical effectiveness of managed alcohol programs for patients with alcohol addiction. Tags alcoholism, harm reduction, residential treatment, substance abuse treatment centers, therapeutic community, addiction, recovery house, residential recovery, community

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Determining the Features of Managed Alcohol Programs

Determining the Features of Managed Alcohol Programs Rapid Synthesis Determining the Features of Managed Alcohol Programs 11 February 2019 McMaster Health Forum 1 Evidence >> Insight >> Action Rapid Synthesis: Determining the Features of Managed Alcohol Programs 30-day response 11 February 2019 Determining the Features of Managed Alcohol Programs 2 Evidence >> Insight >> Action McMaster Health Forum and Forum+ The goal of the McMaster Health Forum, and its Forum+ initiative, is to generate (...) was reviewed by a small number of policymakers, stakeholders and researchers in order to ensure its scientific rigour and system relevance. Acknowledgments The authors wish to thank Jamie Muckle and Bernie Pauly for their insightful comments and suggestions. Citation Mattison CA, Belesiotis P, Wilson MG. Rapid synthesis: Determining the features of managed alcohol programs. Hamilton, Canada: McMaster Health Forum, 11 February 2019. Product registration numbers ISSN 2292-7999 (online)McMaster Health Forum 3

2019 McMaster Health Forum

5. Non-alcoholic fatty liver disease (NAFLD): assessment and management

Non-alcoholic fatty liver disease (NAFLD): assessment and management Non-alcoholic fatty liv Non-alcoholic fatty liver disease er disease (NAFLD (NAFLD): assessment and management ): assessment and management NICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2016 National Institute for Health and Clinical Excellence - Clinical Guidelines

6. Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions

Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested

Full Text available with Trip Pro

2016 NIHR HTA programme

7. Non-alcoholic Fatty Liver Disease, Diagnosis and Management

Non-alcoholic Fatty Liver Disease, Diagnosis and Management The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases Naga Chalasani, 1 Zobair Younossi , 2 Joel E. Lavine, 3 Michael Charlton, 4 Kenneth Cusi, 5 Mary Rinella, 6 Stephen A. Harrison, 7 Elizabeth M. Brunt, 8 and Arun J. Sanyal 9 Preamble This guidance providesadata-supportedapproachto the diagnostic, therapeutic, and preventive aspects (...) or natural history of NAFLD or NASH. The effects of light drinking on the cardio- vascular system and cancer risks, if any, have not been investigatedinindividualswithNAFLD. GuidanceStatements: 34. Patients with NAFLD should not consume heavyamountsofalcohol. 35. There are insuf?cient data to make recommenda- tions with regard to nonheavy consumption of alcohol byindividualswithNAFLD. MANAGEMENT OF CVD AND DYSLIPIDEMIA There is a strong association between NAFLD and increased risk of CVD events

2018 American Association for the Study of Liver Diseases

8. Pathways for management of alcohol withdrawal in critical care units

Pathways for management of alcohol withdrawal in critical care units Pathways for management of alcohol withdrawal in critical care units Pathways for management of alcohol withdrawal in critical care units Mitchell MD, Jablonski, J, Mull, N. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Jablonski, J, Mull, N.. Pathways (...) for management of alcohol withdrawal in critical care units. Philadelphia: Center for Evidence-based Practice (CEP). 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alcoholism; Critical Care; Humans; Intensive Care Units; Substance Withdrawal Syndrome Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System

2017 Health Technology Assessment (HTA) Database.

9. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence

Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence Alcohol-use disorders: diagnosis, Alcohol-use disorders: diagnosis, assessment and management of harmful assessment and management of harmful drinking and alcohol dependence drinking and alcohol dependence Clinical guideline Published: 23 February 2011 nice.org.uk/guidance/cg115 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Alcohol-use disorders: diagnosis, assessment and management

2011 National Institute for Health and Clinical Excellence - Clinical Guidelines

10. Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions

Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management (...) : a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions. Public Health Research 2016; 4(2) Authors' objectives To systematically review the effectiveness of community pharmacy interventions to manage alcohol misuse, smoking cessation and weight loss; to explore if and how age, sex, ethnicity and socioeconomic status moderate effectiveness; and to describe how the interventions have been organised, implemented and delivered. Authors' conclusions Community

2016 Health Technology Assessment (HTA) Database.

11. Alcohol Intake Among Breast Cancer Survivors: Change in Alcohol Use During a Weight Management Intervention (PubMed)

Alcohol Intake Among Breast Cancer Survivors: Change in Alcohol Use During a Weight Management Intervention Daily alcohol intake in quantities as small as half a drink/day significantly increases the risk of breast cancer recurrence for postmenopausal survivors. Interventions designed to modify alcohol use among survivors have not been studied; however, lifestyle interventions that target change in dietary intake may affect alcohol intake.To evaluate change in alcohol use during a weight loss (...) intervention for obese, rural-dwelling breast cancer survivors.Data were derived from an 18-month trial that included a 6-month weight loss intervention delivered via group conference calls, followed by a 12-month randomized weight loss maintenance phase in which participants received continued group calls or mailed newsletters. Participants who reported regular alcohol use at baseline (N=37) were included in this study.Mean daily alcohol intake significantly decreased from baseline to 6 months during

Full Text available with Trip Pro

2016 JMIR cancer

12. Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse. (PubMed)

Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse. Managed alcohol programmes (MAP) are a harm reduction strategy used to minimise the personal harm and adverse societal effects that alcohol dependence can lead to by providing an alternative to zero-tolerance approaches that incorporate drinking goals (abstinence or moderation) that are compatible with the needs of the individual, and promoting access to services by offering (...) this comparison; 22 articles were considered possibly relevant and all were excluded. Most articles were excluded because they failed to compare or consider managed alcohol as the experimental or control intervention, as well as one study (Baker 2010), which was also excluded because study participants were under 18 years of age. No study reviewed offered an intervention that was compared with managed alcohol or considered it as the intervention of interest, providing insufficient evidence to address

2012 Cochrane

13. Alcohol-Related Nurse Care Management in Primary Care: A Randomized Clinical Trial

Alcohol-Related Nurse Care Management in Primary Care: A Randomized Clinical Trial Experts recommend that alcohol use disorders (AUDs) be managed in primary care, but effective approaches are unclear.To test whether 12 months of alcohol care management, compared with usual care, improved drinking outcomes among patients with or at high risk for AUDs.This randomized clinical trial was conducted at 3 Veterans Affairs (VA) primary care clinics. Between October 11, 2011, and September 30, 2014 (...) , the study enrolled 304 outpatients who reported heavy drinking (≥4 drinks per day for women and ≥5 drinks per day for men).Nurse care managers offered outreach and engagement, repeated brief counseling using motivational interviewing and shared decision making about treatment options, and nurse practitioner-prescribed AUD medications (if desired), supported by an interdisciplinary team (CHOICE intervention). The comparison was usual primary care.Primary outcomes, assessed by blinded telephone

2018 EvidenceUpdates

14. Alcohol Withdrawal Management for Acute Care Inpatients

Alcohol Withdrawal Management for Acute Care Inpatients Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Alcohol Withdrawal Management for Acute Care Inpatients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Implementation strategies to improve preconception and antenatal care for tobacco smoking, alcohol consumption and weight management: a systematic review

Implementation strategies to improve preconception and antenatal care for tobacco smoking, alcohol consumption and weight management: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

16. A Preliminary Randomized Controlled Trial of Contingency Management for Alcohol Use Reduction Using a Transdermal Alcohol Sensor. (PubMed)

A Preliminary Randomized Controlled Trial of Contingency Management for Alcohol Use Reduction Using a Transdermal Alcohol Sensor. We tested the efficacy of daily contingent reinforcement for reducing alcohol use compared with (yoked) non-contingent reinforcement (NR) using a transdermal alcohol sensor to detect alcohol use.Pilot randomized controlled design with 1 baseline week, 3 intervention weeks and 1-month follow-up.New England, USA.Heavy drinking adults (46.7% female) not seeking (...) treatment were randomized to (1) an escalating schedule of cash reinforcement (CR; n = 15) for days on which alcohol was neither reported nor detected or (2) yoked NR (n = 15).Reinforcement for CR participants started at $5 and increased $2 every subsequent day on which alcohol was not detected or reported, to a maximum of $17. Participants received no reinforcement for days on which alcohol use was detected or reported, and the reinforcer value was re-set to $5 the day after a drinking day. NR

Full Text available with Trip Pro

2017 Addiction (Abingdon, England)

17. Efficacy of g-csf in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial. (PubMed)

Efficacy of g-csf in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial. Severe alcoholic hepatitis (SAH) is often a progressive disease with high mortality and limited steroid responsiveness. Management options of steroid nonresponsive SAH (day 7 Lille-score>0.45) are limited. We assessed the efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in steroid non-responders.Randomized, double-blind, single-center trial

2019 Hepatology (Baltimore, Md.)

18. Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder. (PubMed)

Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder. Although prenatal alcohol exposure causes craniofacial anomalies, growth retardation, neurological abnormalities, cognitive impairment, and birth defects, fetal alcohol spectrum disorder is underdiagnosed. Global prevalence of fetal alcohol spectrum disorder is 0·77%, with a higher prevalence of 2-5% in Europe and North America, highlighting the need for increased diagnosis and treatment. However, diagnosis (...) remains challenging because of the poor reliability of self-reported maternal drinking histories, an absence of sensitive biomarkers, and the infrequency of diagnostic dysmorphic facial features among individuals with fetal alcohol spectrum disorder. Different diagnostic systems and disagreements over criteria have slowed progress in the diagnosis and management of the disorder. Neuroimaging shows abnormalities in brain structure, cortical development, white matter microstructure, and functional

2019 Lancet Neurology

19. Better Management of Alcohol Liver Disease Using a 'Microstructured Synbox' System Comprising L. plantarum and EGCG. (PubMed)

Better Management of Alcohol Liver Disease Using a 'Microstructured Synbox' System Comprising L. plantarum and EGCG. Synergistic combination of probiotics with carbohydrate based prebiotics is widely employed for the treatment of various gut related disorders. However, such carbohydrate based prebiotics encourage the growth of pathogens and probiotics, equally. Aim of the study was (i) to explore the possibility of using epigallocatechin gallate (EGCG) a phenolic compound, as a prebiotic (...) for L.plantarum; (ii) to develop and evaluate a microstructured synbox (microencapsulating both probiotic and EGCG together) in rat model of alcohol liver disease (ALD); and, (iii) to confirm whether the combination can address issues of EGCG bioavailability and probiotic survivability in adverse gut conditions. Growth enhancing effect of EGCG on L. plantarum (12.8±0.5 log 10 units) was significantly (p≤0.05) better than inulin (11.4±0.38 log 10 units), a natural storage carbohydrate. The formulated synbox

Full Text available with Trip Pro

2017 PLoS ONE

20. Current Management of Alcoholic Hepatitis and Future Therapies (PubMed)

Current Management of Alcoholic Hepatitis and Future Therapies Alcohol is one of the most common etiologies of liver disease, and alcoholic liver disease overall is the second most common indication for liver transplantation in the United States. It encompasses a spectrum of disease, including fatty liver disease, alcoholic hepatitis (AH), and alcoholic cirrhosis. AH can range from mild to severe disease, with severe disease being defined as: Discriminant Function (DF) ≥ 32, or Model for End (...) -stage Liver Disease (MELD) ≥ 21, or presence of hepatic encephalopathy. Management of the mild disease consists mainly of abstinence and supportive care. Severe AH is associated with significant mortality. Currently, there is no ideal medical treatment for this condition. Besides alcohol cessation, corticosteroids have been used with conflicting results and are associated with an inherent risk of infection. Overall steroids have shown short term benefit when compared to placebo, but they have

Full Text available with Trip Pro

2016 Journal of clinical and translational hepatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>